For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $61.88 in the prior trading day, Globus Medical Inc (NYSE: GMED) closed at $61.51, down -0.60%. In other words, the price has decreased by -$0.60 from its previous closing price. On the day, 1.06 million shares were traded. GMED stock price reached its highest trading level at $61.915 during the session, while it also had its lowest trading level at $61.15.
Ratios:
Our goal is to gain a better understanding of GMED by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 36.20 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 15.75. For the most recent quarter (mrq), Quick Ratio is recorded 2.26 and its Current Ratio is at 4.07. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
Morgan Stanley Upgraded its Equal-Weight to Overweight on December 02, 2024, whereas the target price for the stock was revised from $83 to $100.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 28 ’25 when RHOADS ANN D sold 7,500 shares for $78.68 per share. The transaction valued at 590,100 led to the insider holds 35,384 shares of the business.
RHOADS ANN D bought 7,500 shares of GMED for $590,000 on Feb 28 ’25. On Jan 10 ’25, another insider, Pfeil Keith W, who serves as the COO, CFO of the company, sold 14,167 shares for $88.29 each. As a result, the insider received 1,250,770 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GMED now has a Market Capitalization of 8307355136 and an Enterprise Value of 8199334400. As of this moment, Globus’s Price-to-Earnings (P/E) ratio for their current fiscal year is 23.74, and their Forward P/E ratio for the next fiscal year is 16.79. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.49. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.16 while its Price-to-Book (P/B) ratio in mrq is 1.93. Its current Enterprise Value per Revenue stands at 3.122 whereas that against EBITDA is 11.148.
Stock Price History:
The Beta on a monthly basis for GMED is 1.17, which has changed by -0.146761 over the last 52 weeks, in comparison to a change of 0.1590569 over the same period for the S&P500. Over the past 52 weeks, GMED has reached a high of $94.93, while it has fallen to a 52-week low of $51.79. The 50-Day Moving Average of the stock is 7.00%, while the 200-Day Moving Average is calculated to be -14.51%.
Shares Statistics:
The stock has traded on average 1.40M shares per day over the past 3-months and 1080920 shares per day over the last 10 days, according to various share statistics. A total of 112.62M shares are outstanding, with a floating share count of 111.81M. Insiders hold about 17.20% of the company’s shares, while institutions hold 85.40% stake in the company. Shares short for GMED as of 1755216000 were 5442884 with a Short Ratio of 3.90, compared to 1752537600 on 4516423. Therefore, it implies a Short% of Shares Outstanding of 5442884 and a Short% of Float of 5.41.
